Publications
Detailed Information
Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, Hyun Jung | - |
dc.contributor.author | Yang, Jeong Mi | - |
dc.contributor.author | Lee, Jeong-Ok | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Paik, Jin Ho | - |
dc.date.accessioned | 2023-05-08T00:35:40Z | - |
dc.date.available | 2023-05-08T00:35:40Z | - |
dc.date.created | 2019-06-14 | - |
dc.date.created | 2019-06-14 | - |
dc.date.issued | 2018-11 | - |
dc.identifier.citation | Journal of Translational Medicine, Vol.16 No.1, p. 320 | - |
dc.identifier.issn | 1479-5876 | - |
dc.identifier.uri | https://hdl.handle.net/10371/191925 | - |
dc.description.abstract | Background: Antitumor immune response of programmed cell death ligand (PD-L1) has shown clinical value not only in Hodgkin lymphoma and EBV-associated lymphomas but also in EBV-negative diffuse large B cell lymphoma (DLBCL) of non-germinal center B cell-like (non-GCB) subtype. Signal transducer and activator of transcription 3 (STAT3) is known to induce PD-L1 in immune cells and its activated form, phosphorylated STAT3 (pSTAT3), is also frequently expressed in non-GCB DLBCL. Herein, we investigated associations between PD-L1 expression/gene alteration, pSTAT3 expression and clinicopathologic variables in EBV-negative DLBCL. Methods: In 107 cases of DLBCLs with non-GCB subtype (67%; 72/107), GCB subtype (25%; 27/107) and unclassifiable cases (8%; 8/107), we performed PD-L1 and pSTAT3 immunohistochemistry and fluorescence in situ hybridization for PD-L1 gene translocation and copy number gain/amplification. Results: PD-L1 was expressed in tumor cells (PD-L1t) in 21% (23/107; 30% cutoff), immune cells (PD-L1i) in 36% (38/107; 20% cutoff), and pSTAT3 in tumor nuclei in 41% (44/107; 40% cutoff). PD-L1 gene alteration was observed in 10% (10/102) including translocation in 6% (6/102) and copy number gain/amplification in 4% (4/102). Non-GCB subtype was associated with PD-L1t and pSTAT3 (p = 0.006 and p = 0.042), and tended to have PD-L1 gene alteration (p = 0.058). Tumoral PD-L1 expression without gene alteration (PD-L1t + GA-) correlated with pSTAT3-positive tumor cell proportions (%) (p = 0.033). In survival analysis, pSTAT3 expression independently predicted shorter PFS in total cohort (p = 0.017) and R-CHOP-treated group (p = 0.007), and in pSTAT3-negative R-CHOP-treated subset, PD-L1 expression in immune cells (PD-L1i) correlated with shorter PFS (p = 0.042). Conclusions: Gene alteration and protein expression of PD-L1 and pSTAT3 expression were closely related in DLBCL and constituted features of non-GCB subtype. In addition to known clinical significance of pSTAT3, immune cell expression of PD-L1 (PD-L1i) had also clinical value in pSTAT3-dependent manner. These findings may provide an insight into immunotherapeutic strategy and risk stratification in DLBCL patients. | - |
dc.language | 영어 | - |
dc.publisher | BioMed Central | - |
dc.title | Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.1186/s12967-018-1689-y | - |
dc.citation.journaltitle | Journal of Translational Medicine | - |
dc.identifier.wosid | 000450838500001 | - |
dc.identifier.scopusid | 2-s2.0-85056803866 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 320 | - |
dc.citation.volume | 16 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, Jong Seok | - |
dc.contributor.affiliatedAuthor | Paik, Jin Ho | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | DEATH LIGAND 1 | - |
dc.subject.keywordPlus | SIGNAL TRANSDUCER | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | POOR | - |
dc.subject.keywordPlus | OVEREXPRESSION | - |
dc.subject.keywordPlus | TUMORIGENESIS | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Diffuse large B cell lymphoma | - |
dc.subject.keywordAuthor | PD-L1 | - |
dc.subject.keywordAuthor | pSTAT3 | - |
dc.subject.keywordAuthor | Microenvironment | - |
dc.subject.keywordAuthor | Prognosis | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.